Premium
Single‐Dose and Steady‐State Pharmacokinetics of Eslicarbazepine Acetate (BIA 2–093) in Healthy Elderly and Young Subjects
Author(s) -
Almeida Luis,
Falcão Amílcar,
Maia Joana,
Mazur Dago,
Gellert Manfred,
SoaresdaSilva Patrício
Publication year - 2005
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1177/0091270005279364
Subject(s) - scope (computer science) , medicine , computer science , programming language
slicarbazepine acetate (BIA 2-093, S-(-)-10-acetoxy-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide) is a new drug currently in phase III forthetreatmentofepilepsyandphaseIIforbipolardisor-der. It is chemically related to carbamazepine andoxcarbazepine but has been specifically designed toavoid the production of toxic metabolites (such asepoxides) and to overcome enantiomeric impurity andthe unnecessary production of enantiomers ordiastereoisomers of metabolites and conjugates, with-out losing pharmacological activity.